Try our Chrome extension
Easily add the current web-page from your browser directly into your changedetection.io tool, more great features coming soon!
Chrome Webstore
Changedetection.io needs your support!
You can help us by supporting changedetection.io on these platforms;
- Rate us at AlternativeTo.net
- Star us on GitHub
- Follow us at Twitter/X
- G2 Software reviews
- Check us out on LinkedIn
- And tell your friends and colleagues :)
The more popular changedetection.io is, the more time we can dedicate to adding amazing features!
Many thanks :)
changedetection.io team
Not yet seconds ago
False
Not yet seconds ago
Triggered text Ignored text Blocked text
2 hours ago
* Skip to content
* Skip to search
* Behind the Science magazine
* Company
+
+ Company
+ Purpose, strategy and culture
+ Outstanding people
o
o Outstanding people
o Great place to work
o Meet our veterans
o Working together
o My GSK story
o Innovating together
+ GSK at a glance
+ History and heritage
+ Board of Directors and Executive Committee
+ Board information
+ Governance
o
o Governance
o Committees
o Shareholders
o Sarbanes-Oxley Act 2002
o Compliance
+ Policy positions
+ Codes, standards and reports
* Innovation
+
+ Innovation
+ Our leading scientists
o
o Our leading scientists
o Dr Tony Wood
o Dr Sabine Luik
o Dr Hesham Ahmed Abdullah
o Dr Kaivan Khavandi
+ Research and development approach
+ Pipeline
+ Therapeutic areas
o
o Therapeutic areas
o Respiratory, immunology and inflammation
o Oncology
o HIV
o Infectious diseases
+ Tech
+ Clinical trials at GSK
o
o Clinical trials at GSK
o Provision of unapproved medicines for unmet medical needs
o Data transparency
o Representative clinical studies
+ Partnering with GSK
o
o Partnering with GSK
o Supported studies
+ R&D locations
* Products
+
+ Products
+ Product areas
+ Products A-Z
* Responsibility
+
+ Responsibility
+ Access
+ Global health and health security
o
o Global health and health security
o Global health
o Health security
o Using our science for global health
o Improving access to healthcare
o Africa Open Lab
+ Environment
o
o Environment
o Climate
o Freshwater
o Land
o Oceans
o Atmosphere
o Materials and waste
o Health system sustainability
+ Inclusion
+ Ethical standards
o
o Ethical standards
o Working with third parties
o Public policy and patient advocacy
o Human rights
o Use of animals
o Engaging with healthcare professionals
+ Product governance
+ Grants and donations
+ Charitable investments
+ Responsibility reports
o
o Responsibility reports
o Reports archive
* Investors
+
+ Investors
+ Why invest in GSK?
+ Quarterly results
+ Financial reports
o
o Financial reports
o Annual Report 2024
o Corporate reports archive
+ Responsible business
+ Speeches and presentations
+ Science publications
+ Events calendar
+ Dividend and share price
o
o Dividend and share price
o GSK share price
o Share price calculators (GBp/USD)
o Dividend calculators (GBp/USD)
o Dividend calendar
+ Analyst consensus
+ Stock exchange announcements
o
o Stock exchange announcements
o London (RNS)
o London (RNS) inside information
o New York (SEC)
o Sign up for announcements
+ Shareholder information
o
o Shareholder information
o Manage your shares
o Annual General Meeting
o General Meeting
o Annual Governance Meeting
o Corporate sponsored nominee service
o Our ADR programme
o Asset reunification - Georgeson
o Share scam alert
o Privacy notice for ordinary shareholders
o FAQs
+ Corporate actions
o
o Corporate actions
o Consumer Healthcare Demerger
o Consumer Healthcare Joint Venture
o Agreement to acquire TESARO
+ Debt investors
+ Investor contacts
* Media
+
+ Media
+ Press releases
+ Media contacts
+ Media library
+ Zantac litigation
+ Our social media
+ Podcasts
+ RSS feeds
* Careers
+
+ Careers
+ Search jobs
+ Featured careers
o
o Featured careers
o A career in data
+ Life at GSK
+ Experienced professionals
o
o Experienced professionals
o Business operations
o Engineering at GSK
o Global supply chain
o Sales and marketing
o Research and development
-
- Research and development
- Chemical Manufacturing and Controls (CMC), Medicine Development and Supply (MDS)
- Genomic sciences
o Technology
+ Early careers
o
o Early careers
o Application process
o Apprentice programmes
o Internships and placements
o Graduate programme
-
- Graduate programme
- Business operations
- Engineering
- Manufacturing & supply
- Commercial
- Research & development
- Digital & tech
- Manufacturing sciences & technology
o Post graduate opportunities
o Frequently asked questions
+ Veterans
+ Our global and regional hubs
+ How we hire
o
o How we hire
o Fraudulent internet recruitment activities
o Frequently asked questions
* Dark mode
Switch to dark mode to head towards a more sustainable world together. More info
* Healthcare professionals
* Contact us
GSK Homepage
Search Menu
* Global
* Change location
* Dark mode
Switch to dark mode to head towards a more sustainable world together. More info
* Healthcare professionals
* Contact us
* Search
GSK Homepage
* Behind the Science magazine
* Company
* Innovation
* Products
* Responsibility
* Investors
* Media
* Careers
Media
Latest press releases, media assets and global media contacts
Press releasesAnnual Report 2024
Close video
Scroll to explore
Latest press releases
For media and investors
25 February 2026
GSK enters agreement to acquire 35Pharma Inc.
18 February 2026
ViiV Healthcare’s long-acting Cabenuva (cabotegravir + rilpivirine) for HIV demonstrates superior efficacy compared to daily oral therapy for people with adherence challenges; results published in NEJM
17 February 2026
GSK’s Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows
17 February 2026
Exdensur (depemokimab) approved by the European Commission for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
10 February 2026
GSK’s RSV vaccine, Arexvy, accepted for regulatory review in China for adults aged 60 years and older
06 February 2026
Nucala (mepolizumab) approved by the European Commission for the treatment of chronic obstructive pulmonary disease (COPD)
04 February 2026
GSK delivers strong 2025 performance and re-affirms long-term outlooks
26 January 2026
GSK’s RSV vaccine, Arexvy, receives European approval for expanded use in all adults 18 years and older
23 January 2026
Trelegy Ellipta approved in China for use in adults with uncontrolled asthma
20 January 2026
GSK enters agreement to acquire RAPT Therapeutics
20 January 2026
GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding
07 January 2026
GSK’s Shingrix (Recombinant Zoster Vaccine) prefilled syringe presentation approved by the European Commission
07 January 2026
GSK announces positive results from B-Well 1 and B-Well 2 phase III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B
06 January 2026
Exdensur (depemokimab) approved in Japan for severe asthma and chronic rhinosinusitis with nasal polyps
05 January 2026
Nucala (mepolizumab) approved in China for use in adults with chronic obstructive pulmonary disease (COPD)
19 December 2025
GSK enters agreement with U.S. government to lower drug prices and expand access to respiratory medicines for millions of Americans
16 December 2025
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
15 December 2025
Exdensur (depemokimab) approved in the UK for treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
12 December 2025
Nucala (mepolizumab) receives positive CHMP opinion for treatment of chronic obstructive pulmonary disease (COPD)
12 December 2025
Depemokimab receives positive CHMP opinion for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps
12 December 2025
GSK’s RSV vaccine, Arexvy, receives positive CHMP opinion for all adults 18 years and older
11 December 2025
Blujepa (gepotidacin) approved by US FDA as oral option for treatment of uncomplicated urogenital gonorrhoea (uGC)
10 December 2025
GSK’227, a B7-H3-targeted antibody-drug conjugate, granted Orphan Drug Designation in small-cell lung cancer by the US FDA
01 December 2025
GSK data at ASH show potential to redefine outcomes for people living with blood cancers
20 November 2025
TESARO, a GSK subsidiary, initiates litigation against AnaptysBio, Inc.
19 November 2025
GSK and LTZ announce strategic collaboration to advance novel myeloid cell engagers in oncology
18 November 2025
GSK and Fleming Initiative scientists unite to target AMR with advanced AI
07 November 2025
GSK presents data from its advancing liver pipeline at AASLD 2025
29 October 2025
GSK delivers strong Q3 performance and upgrades 2025 guidance
28 October 2025
GSK and Empirico enter license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases
28 October 2025
GSK’s B7-H3-targeted antibody-drug conjugate, GSK’227, receives Orphan Drug Designation in the EU
27 October 2025
GSK acquires exclusive rights from Syndivia for antibody-drug conjugate (ADC) in prostate cancer
23 October 2025
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma
22 October 2025
GSK announces positive pivotal phase III data for next-generation low carbon version of Ventolin (salbutamol) metered dose inhaler
21 October 2025
GSK’s Shingrix new prefilled syringe presentation receives positive CHMP opinion
21 October 2025
Positive PIVOT-PO phase III data show tebipenem HBr’s potential as the first oral carbapenem antibiotic for patients with complicated urinary tract infections (cUTIs)
20 October 2025
Global Fund welcomes renewed commitment from GSK and ViiV Healthcare to expand community-led health solutions with £6 million joint pledge ahead of 8th Replenishment
15 October 2025
ViiV Healthcare’s CLARITY study shows long-acting cabotegravir more acceptable than lenacapavir injections after a single dose, with 90% preferring cabotegravir
14 October 2025
GSK’s Shingrix approved in China for prevention of shingles in adults aged 18 and over who are at increased risk due to immunodeficiency or immunosuppression
29 September 2025
Luke Miels appointed CEO designate for GSK
22 September 2025
GSK to submit label update for Wellcovorin (leucovorin) at US FDA’s request
17 September 2025
GSK to invest $30 billion in R&D and Manufacturing in the United States over next 5 years
15 September 2025
GSK to showcase new research from its broad respiratory portfolio at the European Respiratory Society (ERS) Congress 2025
11 August 2025
Gepotidacin accepted for priority review by the US FDA for the oral treatment of uncomplicated urogenital gonorrhoea
08 August 2025
GSK provides update on US settlement of CureVac/BioNTech mRNA patent litigation
30 July 2025
GSK delivers continued strong performance
29 July 2025
GSK highlights new findings on Dementia and Alzheimer’s Disease at AAIC 2025, building on leadership in immunology and inflammation
28 July 2025
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
24 July 2025
Blenrep (belantamab mafodotin) combinations approved in EU for treatment of relapsed/refractory multiple myeloma
23 July 2025
GSK announces extension of US Food and Drug Administration review period for Blenrep (belantamab mafodotin-blmf) in relapsed/refractory multiple myeloma
Behind the Science
Read our latest articles
Mapping disease at the cellular level: A single-cell revolution in drug discovery
Why adults aged 50 years and older with certain long-term health conditions need to make their move to help protect against this common respiratory virus
'The ever-present threat of contracting a UTI means my daily routine is ruled by measures to reduce my risk'
'We’re innovating to help keep COPD patients out of hospital and exacerbation-free'
'Prevention is the best medicine to stop disease before it starts'
‘I was the sickest anyone could ever be’: Why young people are at risk of meningitis and what needs to change to reduce it
‘Digital biological twins and organoids might sound like sci-fi, but they’re real – and we’re using them to fight cancer’
‘I feel hopeless and frustrated’: Why patients living with incurable blood cancers need more treatment options
‘Finding the right treatment for my asthma and nasal polyps has transformed my life. I hope my experience can help others achieve the same’
‘How do we improve trust in prevention? The answer lies closer to home than you might think’
Behind the Science magazine
Media Contacts
Are you a professional journalist with an enquiry for our media team?
Get in touch
Media library
Explore our images and videos for use in the media.
Image
Scientists collaborating and conducting vaccine research
Image
Vaccines manufacturing, Jurong
Image
AI Hub, Kings Cross, London
Image
Manufacturing employee at work, singapore
Image
Stevenage R&D site, UK
Image
Luke Miels
Our media library
In the spotlight
2025 Full year and fourth quarter results announcement
Quarterly results
04 February 2026
We announced our fourth quarter 2025 results at 07:00 GMT, 02:00 EST on Wednesday 4 February.
GSK at a glance
Quick facts and figures with a downloadable PDF
GSK at a glance
2024 Annual Report and Responsible Business Performance Report published
Annual Report 2024
Responsibility reports
27 February 2025
You might also like
Our leading scientists
Meet the world-leading scientists who are uniting science, technology and talent to get ahead of disease together.
GSK at a glance
We prioritise innovation in specialty medicines and vaccines to prevent and treat disease.
Global health
We are changing the trajectory of high burden diseases in lower income countries, with a focus on infectious diseases.
Continue to Careers
Gsk Logo
This is our global website, intended for visitors seeking information on GSK's worldwide business. Our market sites can be reached by visiting our location selector.
© 2001-2026 GSK plc. All rights reserved. Trade marks are owned by or licensed to the GSK group of companies.
GSK plc. Registered in England and Wales No. 3888792.
Registered office: 79 New Oxford Street, London. United Kingdom. WC1A 1DG
> Modern Slavery Act Statement 2024 (PDF - 162.5KB)
GSK websites
* Locations selector
* Social media directory
* GSKPro for healthcare professionals
* GSK study register
* Supplier website
* ViiV Healthcare
Quick links
* Behind the Science magazine
* Company
* Innovation
* Products
* Responsibility
* Investors
* Media
* Careers
Get in touch
* Contact us
* Partnerships
* Report a possible side effect
* GSK Speak up
Follow us on:
*
*
*
*
*
*
*
* Accessibility
* Digital sustainability
* Terms of use
* Cookie policy
* Privacy notice
* Sitemap
For now, Differences are performed on text, not graphically, only the latest screenshot is available.
Screenshot requires a Content Fetcher ( Sockpuppetbrowser, selenium, etc ) that supports screenshots.